GC said Thursday that it has administered the first dose of MG1113, a hemophilia treatment, to a patient participating in phase 1 clinical trial for the drug.

GC headquarters in Yongin, Gyeonggi Province.

The company plans to evaluate the safety of MG1113 in 49 healthy adults and hemophilia patients at two hospitals -- Severance Hospital and Korea University Anam Hospital.

Compared to conventional methods of injecting insufficient blood coagulation factors, MG1113 is a therapeutic agent made of antibodies that activate coagulation factors.

Due to the nature of the antibody treatment, patients who are resistant to conventional drugs can receive the medication, while the candidate will cover both type A and type B hemophilia.

Also, MG1113 is a high-concentration formulation with a longer half-life than conventional drugs, while patients can receive the medication through subcutaneous injection.

“This can lead to dramatic improvements in patient convenience, as the number of medications and pain can be reduced,” the company said.

GC Head of Medical Division Kim Jin said, “After confirming the therapeutic effect through this study, we plan to accelerate research for commercialization.”

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>